-->

On:

SHENZHEN, Dec 15, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing. In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1].  In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future. Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo. The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries). About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.  Reference: 1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib 2. Datas are from the China Insights Consultancy (CIC) report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

-->

On:

Bangkok, Thailand | 8–12 December 2025 — ANGEL participated in the IWA Water and Development Congress & Exhibition (WDCE), showcasing solutions for medium and large-scale water treatment projects and bottleless RO water dispensers for public and office use. Zhao Kai, Vice President of ANGEL Group, attended the opening and delivered remarks, highlighting ANGEL’s innovation and its commitment to international collaboration for sustainable development. The congress, co-hosted by IWA and the Asian Institute of Technology under the theme “Water, sanitation, and innovation – pathways to progress and a resilient future”, brought together around 2,000 participants from over 90 countries and regions. Reshaping the Landscape of Intelligent Water-Quality Monitoring  On 9 December, Lei Jing, a technical expert from ANGEL’s Central Research Institute, presented ANGEL’s patented AIMS precision ion-sensing technology at a WDCE thematic forum, drawing strong interest from global water-sector experts. As demand grows for accurate control of mineral-ion concentrations, AIMS addresses long-standing limits of conventional ion-detection devices. With an innovative electrode design, it reduces electrode loss, improves accuracy, and avoids frequent calibration. It upgrades monitoring from manual estimation and periodic sampling to real-time feedback and intelligent control, combining high-precision measurement with data visualisation. AIMS has won a Gold Medal at the Geneva International Exhibition of Inventions. Optimised for cost and size, AIMS can be integrated into a wide range of water-treatment equipment and remain stable over long-term use without routine calibration. Beyond household water applications, it shows promise across research, biomedicine, environmental protection, and industrial and agricultural sectors—potentially lowering carbon footprints and supporting water recycling for more sustainable water management. A New Paradigm for Efficient, Long-Lasting Water Disinfection  On 11 December at the IWA WDCE, Chen Qingyan, technical expert at ANGEL’s Central Research Institute, presented ANGEL’s new water-disinfection technology and its purification applications in the session on emerging contaminants and disinfection. Addressing bacterial contamination in long-used purifiers, ANGEL spent seven years developing APCM “space-grade” antimicrobial technology, which physically attracts bacteria and ruptures cell membranes, achieving up to a 99.99% removal rate against ESKAPE pathogens. Conference experts viewed it as a promising new approach to drinking-water safety, and ANGEL drew strong attention for its innovative, scenario-based solutions and its commitment to advancing efficient, intelligent, and environmentally sustainable water treatment.

-->

On:

กรุงเทพฯ ประเทศไทย | 8–12 ธันวาคม 2025 — ANGEL เข้าร่วมงาน IWA Water and Development Congress & Exhibition (WDCE) โดยนำเสนอโซลูชันสำหรับโครงการบำบัดน้ำขนาดกลางและขนาดใหญ่ รวมถึงตู้กดน้ำ RO แบบไม่ใช้ขวดสำหรับการใช้งานในพื้นที่สาธารณะและสำนักงาน จ้าว ไค รองประธานกลุ่มบริษัท ANGEL เข้าร่วมพิธีเปิดและกล่าวสุนทรพจน์ เน้นย้ำถึงนวัตกรรมของ ANGEL และความมุ่งมั่นในการร่วมมือระดับนานาชาติเพื่อการพัฒนาที่ยั่งยืน การประชุมซึ่งจัดร่วมกันโดย IWA และสถาบันเทคโนโลยีแห่งเอเชีย ภายใต้หัวข้อ “น้ำ สุขาภิบาล และนวัตกรรม – เส้นทางสู่ความก้าวหน้าและอนาคตที่ยืดหยุ่น” ได้รวบรวมผู้เข้าร่วมประมาณ 2,000 คนจากกว่า 90 ประเทศและภูมิภาค เมื่อวันที่ 9 ธันวาคม เหลย จิ้ง ผู้เชี่ยวชาญด้านเทคนิคจากสถาบันวิจัยกลางของ ANGEL ได้นำเสนอเทคโนโลยีตรวจวัดไอออนความแม่นยำสูง AIMS ที่ได้รับสิทธิบัตรของ ANGEL ในเวทีเสวนาเฉพาะด้านของ WDCE ซึ่งได้รับความสนใจอย่างมากจากผู้เชี่ยวชาญด้านน้ำจากทั่วโลก ท่ามกลางความต้องการที่เพิ่มขึ้นในการควบคุมความเข้มข้นของไอออนแร่ธาตุอย่างแม่นยำ AIMS เข้ามาแก้ไขข้อจำกัดที่มีมานานของอุปกรณ์ตรวจจับไอออนแบบดั้งเดิม ด้วยการออกแบบอิเล็กโทรดที่เป็นนวัตกรรม ช่วยลดการสึกหรอของอิเล็กโทรด เพิ่มความแม่นยำ และหลีกเลี่ยงความจำเป็นในการปรับเทียบบ่อยครั้ง เทคโนโลยีนี้ยกระดับการตรวจวัดจากการประเมินด้วยมือและการเก็บตัวอย่างเป็นระยะ ไปสู่การตอบสนองแบบเรียลไทม์และการควบคุมอัจฉริยะ ผสานการวัดที่มีความแม่นยำสูงเข้ากับการแสดงผลข้อมูลอย่างเป็นภาพ AIMS ได้รับรางวัลเหรียญทองจากงาน Geneva International Exhibition of Inventions AIMS ได้รับการปรับให้เหมาะสมทั้งด้านต้นทุนและขนาด สามารถผสานรวมเข้ากับอุปกรณ์บำบัดน้ำหลากหลายประเภท และคงความเสถียรในการใช้งานระยะยาวโดยไม่ต้องปรับเทียบเป็นประจำ นอกเหนือจากการใช้งานในครัวเรือนแล้ว เทคโนโลยีนี้ยังมีศักยภาพในงานวิจัย ชีวการแพทย์ การคุ้มครองสิ่งแวดล้อม รวมถึงภาคอุตสาหกรรมและการเกษตร ซึ่งอาจช่วยลดคาร์บอนฟุตพริ้นต์และสนับสนุนการรีไซเคิลน้ำ เพื่อการจัดการทรัพยากรน้ำที่ยั่งยืนยิ่งขึ้น กระบวนทัศน์ใหม่ของการฆ่าเชื้อน้ำที่มีประสิทธิภาพและยาวนาน เมื่อวันที่ 11 ธันวาคม ในงาน IWA WDCE เฉิน ชิงเหยียน ผู้เชี่ยวชาญด้านเทคนิคจากสถาบันวิจัยกลางของ ANGEL ได้นำเสนอเทคโนโลยีการฆ่าเชื้อน้ำรูปแบบใหม่ของ ANGEL และการประยุกต์ใช้ในการทำให้น้ำบริสุทธิ์ ภายในหัวข้อการประชุมว่าด้วยสารปนเปื้อนเกิดใหม่และการฆ่าเชื้อ เพื่อตอบโจทย์ปัญหาการปนเปื้อนของแบคทีเรียในเครื่องกรองน้ำที่ใช้งานมาเป็นเวลานาน ANGEL ใช้เวลากว่าเจ็ดปีในการพัฒนาเทคโนโลยีต้านจุลชีพ APCM ระดับ “อวกาศ” ซึ่งอาศัยการดึงดูดแบคทีเรียทางกายภาพและทำลายเยื่อหุ้มเซลล์ ส่งผลให้สามารถกำจัดเชื้อก่อโรคกลุ่ม ESKAPE ได้สูงถึง 99.99% ผู้เชี่ยวชาญในการประชุมมองว่าเทคโนโลยีนี้เป็นแนวทางใหม่ที่มีศักยภาพในการยกระดับความปลอดภัยของน้ำดื่ม และ ANGEL ได้รับความสนใจอย่างมากจากโซลูชันเชิงนวัตกรรมที่ออกแบบตามสถานการณ์จริง รวมถึงความมุ่งมั่นในการผลักดันการบำบัดน้ำที่มีประสิทธิภาพ อัจฉริยะ และเป็นมิตรต่อสิ่งแวดล้อม

On:

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

-->

On:

New York, NY – December 08, 2025 – (SeaPRwire) – CryptoFeeDiscount, a premier cryptocurrency data aggregation platform, today announced the official launch of its advanced Crypto Trading Fee Savings Calculator. Designed for quant institutions and high-volume traders, this new data-driven engine reveals hidden transaction costs and identifies optimized execution strategies to reduce trading fees by up to 30%. As crypto market volatility increases in late 2025, transaction costs have become a silent profit killer for active traders. A typical futures trader generating $5 to $10 million in monthly volume can lose upwards of $400 to $600 per month in unnecessary maker/taker fees without optimized account structuring. CryptoFeeDiscount addresses this issue by providing a transparent, data-driven interface that allows users to: Compare Real-Time Rates: Instantly visualize the cost difference between top-tier derivatives exchanges like Bitget and Binance. Unlock VIP Fee Discounts for Free: Access exclusive, institutional-grade fee reductions usually reserved for VIP 1-3 levels, bypassing standard trading volume requirements. Verify Promo Codes: Utilize the platform’s database of verified Referral Codes and Promo Codes to ensure maximum sign-up bonuses and lifetime fee rebates. Discover Niche Opportunities: Filter exchanges by specific criteria, such as “Privacy-First” features for secure trading or high-leverage trading options. “Most retail traders obsess over entry and exit prices but completely ignore the frictional cost of trading,” said James Anderson, Lead Analyst at CryptoFeeDiscount. “Our data shows that by simply switching execution venues or applying a verified discount code on platforms like Bitget, a scalper can increase their net profitability by over 15% annually. We built this calculator to make that math visible and actionable.” The platform has already verified and indexed active promo codes for major platforms, ensuring users have access to the lowest possible rates currently available on the market, with savings reaching up to 30% on select crypto exchanges. ABOUT CRYPTOFEEDISCOUNT CryptoFeeDiscount is a leading financial technology website dedicated to transparency in cryptocurrency trading costs. Through its proprietary comparison engine and rigorous verification process, the platform helps traders find the best execution venues, referral codes, and sign-up bonuses. MEDIA CONTACT Brand: CryptoFeeDiscount   Contact: James Anderson Email: team@CryptoFeeDiscount.com Website: https://CryptoFeeDiscount.com

-->

On:

Legiit Takes a Bold Step Forward with a Fresh Look and Expanded Offerings for Comprehensive Digital Marketing Myrtle Beach, SC – October 20, 2024 – (SeaPRwire) – Legiit, a leading digital marketplace for SEO and marketing services, has rebranded with a new logo and is setting the stage for the next chapter in its journey. With a focus on maintaining its strong foundation in SEO and backlink services, Legiit also plans to introduce new categories that will provide even more value to businesses seeking a one-stop solution for their marketing needs. Legiit remains committed to delivering exceptional link building services, a critical component in improving search engine rankings and driving online visibility. The platform offers a variety of link building packages designed to meet the needs of businesses at every stage of their digital marketing journey. Freelancers on Legiit specialize in providing high-quality backlinks, which are essential for boosting a website’s authority in search engine results. Offerings include foundation backlinks, Google and Amazon cloud backlinks, advanced link building services, and private blog network (PBN) services. Additionally, businesses can benefit from press releases, blog comment links, profile links, guest posting, and niche edit links to strengthen their online presence. These link building services ensure that Legiit clients have access to proven strategies to enhance their SEO efforts and maximize their digital marketing impact. Legiit’s dedication to enhancing local visibility for businesses is evident through its comprehensive local SEO services. For companies looking to dominate their local markets, Legiit provides access to thousands of freelance local SEO experts. These professionals offer targeted local SEO packages designed to improve Google Maps rankings and optimize Google Business Profiles. From boosting search engine visibility to driving more local traffic and generating leads, Legiit’s local SEO service is tailored to help businesses stand out in their communities. The platform’s experts offer strategies that include optimizing business listings and using the latest local SEO techniques to ensure that companies reach their target audiences effectively. Legiit’s rebranding marks more than just a visual transformation; it represents the company’s vision to continually evolve its offerings and meet the changing needs of businesses in the digital marketing landscape. The upcoming launch of new service categories will broaden Legiit’s capabilities, positioning it as an all-in-one solution for marketing strategies beyond SEO. These new categories will encompass other digital marketing channels, allowing businesses to leverage Legiit as their go-to resource for comprehensive growth strategies. As the company expands its focus, its mission remains clear—to provide businesses with effective tools and services that drive results. About Legiit Legiit is a dynamic digital marketplace connecting businesses with top freelance talent specializing in SEO, link building, local SEO, and a wide range of digital marketing services. With a commitment to delivering value through innovative strategies, Legiit aims to empower businesses to achieve their marketing goals. The platform offers tailored services that cater to both startups and established companies looking to enhance their online presence and grow their customer base. To explore Legiit’s offerings, visit Legiit. Media Contact Brand: Legiit Contact: Media team Email: help@legiit.com Website: https://legiit.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...